BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Apr 25, 2011
 |  BC Week In Review  |  Clinical News  |  Regulatory

Octagam regulatory update

EMA's CHMP recommended lifting marketing suspension of Octapharma's Octagam 5% and 10% human IV immunoglobulin in the EU following implementation of an improved manufacturing process and other preventive measures. Last year, EMA recommended marketing...

Read the full 148 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >